Valneva (VALN) said Tuesday the European Commission granted marketing authorization for the Ixchiq vaccine to prevent chikungunya in adolescents aged 12 and older.
The approval was based on data from a six-month Phase 3 study in Brazil, which showed that a single dose induced a high immune response in 99.1% of adolescents.
The company said Ixchiq is now approved for adults and adolescents in the European Union, alongside approvals in the US, UK, and Canada.
Shares of Valneva were up over 1% in recent trading.
Price: 6.79, Change: +0.08, Percent Change: +1.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。